GentiBio
Gene Uenishi is a Senior Scientist in the Discovery group at GentiBio. Prior to joining GentiBio, Gene was a Scientist at BlueRock Therapeutics, where he developed the iPSC-derived Treg program and helped establish the research group in Boston, MA. He started his career in industry at Casebia Therapeutics working on gene editing HSCs and T-cells to cure rare genetic hematological and autoimmune diseases. During his graduate work, he was a project consultant for Waisman Biomanufacturing assisting with tech transfer for Cynata Therapeutics’ first iPSC-derived mesenchymal stem cell therapy to treat graft-vs-host disease. Gene received his B.A. in psychology from Carleton College and his Ph.D. in Cell and Molecular Pathology from University of Wisconsin – Madison.
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.